Arcellx (ACLX)
(Delayed Data from NSDQ)
$65.92 USD
+2.57 (4.06%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $65.89 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Brokerage Reports
Arcellx, Inc. [ACLX]
Reports for Purchase
Showing records 1 - 13 ( 13 total )
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Recap: Tech Transfer to Kite Complete; iMMagine-3 Study to Initiate in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Recap: Abecma/Carvykti ODAC Meeting on March 15 to be a Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
Data at ASH Reinforce Anito-Cel as a Safe and Effective BCMA CAR-T Therapy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ACLX 12123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
Expansion of Kite Partnership Increases Our Confidence in CART-ddBCMA Success; Increasing PT to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Recap: Durability Update With 26.5 Months Follow-Up Expected at ASH 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
ASH Abstract Indicates CART-ddBCMA Median PFS Could Beat Carvykti in CARTITUDE-1
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Recap: Partial Clinical Hold Lifted by FDA For iMMagine-1, Removing a Minor Setback
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Hold on iMMagine-1 Is a Minor Setback and Does Not Change Fundamental Story
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Take: Positive BCMA CAR-T Competitor Data Increase Our Confidence in CART-ddBCMA; Increasing PT to $49
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Take: Focus Remains on Completing Enrollment For iMMagine-1 Study in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Arcellx, Inc.
Industry: Medical - Biomedical and Genetics
A Small Binding Domain With Big Impact; Initiating at Buy and $42 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
|